Precirix is a private biotechnology company dedicated to extending and improving the lives of cancer patients by designing and developing novel radiopharmaceuticals, using camelid-derived single-domain antibodies (sdAb) labeled with radioisotopes.
CAM-H2, a HER2-directed sdAb combined with iodine-131 recently completed a Phase I clinical study. The company’s Fibroblast Activation Protein (FAP)-targeting program is transitioning into the clinic.
The company’s technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy. In addition to CAM-FAP and CAM-H2, the company has product candidates in preclinical stage and is further broadening its platform through research on isotopes, linker technology and combination therapies.
Your browser is not supported. Update your browser for more security, speed and to make the most of this site.